MediastinitisMEDIASTINITISNCT05001308
Infectious Mediastinitis Among the Strasbourg Universitary Hospital
An observational study of Mediastinitis, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Mediastinitis are rare but serious infections, with mortality rates varying from 6 to 30% according to the literature. They are essentially linked to surgical management (cardio-thoracic in particular), but some forms can be spontaneous, after extension of an ENT infectious focus, for example. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Mediastinitis
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jun 2021to 31 May 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Subject diagnosed with mediastinitis between 01/01/2010 and 31/12/2020
Who may be able to join
- Major subject (≥18 years old)
- Subject diagnosed with mediastinitis between 01/01/2010 and 31/12/2020
- Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research.
Who cannot join
- Subject having expressed opposition to participate in the study
- Subject under guardianship, curatorship or safeguard of justice
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
Service de maladies infectieuses et tropicales - Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091
Yvon RUCH, MD, 33.3.69.55.12.19, yvon.ruch@chru-strasbourg.fr
Saïd CHAYER, PhD, HDR, 33 3 88 11 66 90, said.chayer@chru-strasbourg.fr
About this study
Official title: Infectious Mediastinitis Among the Strasbourg Universitary Hospital, a Retrospective Cohort
Mediastinitis are rare but serious infections, with mortality rates varying from 6 to 30% according to the literature. They are essentially linked to surgical management (cardio-thoracic in particular), but some forms can be spontaneous, after extension of an ENT infectious focus, for example.
Despite their seriousness, there is no strong recommendations to define their management, especially concerning antibiotic therapy and its duration.
The aim of this research is to make a descriptive analysis of the cases of mediastinitis at HUS in recent years, and to study the therapeutic strategy used
- Conditions
- Mediastinitis
- Keywords
- Mediastinitis, Sternitis, Deep Sternal Wound Infection
- Medical subject headings
- Mediastinitis
What is being measured
The primary outcome is the main question the study is designed to answer.
Analysis of the cases of mediastinitis and the therapeutic strategy used in recent years at University Hospitals of Strasbourg
Measured: Files analysed retrospectively from January 01, 2010 to December 31, 2020 will be examined]
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2021
- Study start1 Jun 2021
- Primary completionMay 2022 (estimated)
- Study completion31 May 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MediastinitisStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Yvon RUCH, MD, Principal investigator, Service de maladies infectieuses et tropicales - Hôpitaux Universitaires de Strasbourg
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05001308
- Sponsor's protocol ID
- 8262
- Acronym
- MEDIASTINITIS
- Status last verified
- Aug 2021
- First submitted
- 6 Aug 2021
- Last updated
- 2 Dec 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Infectious Mediastinitis Among the Strasbourg Universitary Hospital, a Retrospective Cohort
- ClinicalTrials.gov ID
- NCT05001308
- Acronym / sponsor ID
- MEDIASTINITIS / 8262
- Conditions
- Mediastinitis
- Keywords
- Mediastinitis, Sternitis, Deep Sternal Wound Infection
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 1 Jun 2021 (actual)
- Primary completion
- May 2022 (estimated)
- Study completion
- 31 May 2022 (estimated)
- First posted
- 11 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Mediastinitis are rare but serious infections, with mortality rates varying from 6 to 30% according to the literature. They are essentially linked to surgical management (cardio-thoracic in particular), but some forms can be spontaneous, after extension of an ENT infectious focus, for example.
Despite their seriousness, there is no strong recommendations to define their management, especially concerning antibiotic therapy and its duration.
The aim of this research is to make a descriptive analysis of the cases of mediastinitis at HUS in recent years, and to study the therapeutic strategy used
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Subject diagnosed with mediastinitis between 01/01/2010 and 31/12/2020
Key inclusion criteria (3 listed)
- Major subject (≥18 years old)
- Subject diagnosed with mediastinitis between 01/01/2010 and 31/12/2020
- Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research.
Key exclusion criteria (2 listed)
- Subject having expressed opposition to participate in the study
- Subject under guardianship, curatorship or safeguard of justice
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Analysis of the cases of mediastinitis and the therapeutic strategy used in recent years at University Hospitals of Strasbourg
Time frame: Files analysed retrospectively from January 01, 2010 to December 31, 2020 will be examined]
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2021.
Related trials for Mediastinitis
Not yet recruitingPhase 4
Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients
Cardiovascular Disease, Surgical Site Infection
Not yet recruitingObservational study
Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections.
Soft Tissue Infections, Mediastinitis
Active, not recruitingObservational study
The Role of Inflammatory Biomarkers in Preventing Deep Sternal Wound Infections After Sternotomy
Deep Sternal Infection, Diabete Mellitus
Not yet recruiting
Antibiotics Distribution Study in Peripheral Compartments: Contribution of Microdialysis
Children in Cardiac Intensive Care Requiring Surgery for Congenital Heart Disease
Recruiting
Study on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension
Fibrosing Mediastinitis, Pulmonary Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yvon RUCH, MD principal investigator
Service de maladies infectieuses et tropicales - Hôpitaux Universitaires de Strasbourg
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Mediastinitis, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yvon RUCH, MD (33 3 69 55 12 19, yvon.ruch@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Analysis of the cases of mediastinitis and the therapeutic strategy used in recent years at University Hospitals of Strasbourg (time frame: Files analysed retrospectively from January 01, 2010 to December 31, 2020 will be examined]). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2021.